Supplementary Materials

The PDF file includes:

  • Fig. S1. Schematic overview of TARDIS.
  • Fig. S2. Comparison of raw and TARDIS-corrected background errors.
  • Fig. S3. Comparison of total cfDNA concentration between plasma samples from patients and healthy volunteers.
  • Fig. S4. Variant and tumor fractions in individual patients.
  • Fig. S5. Receiver operating characteristic curve for predicting residual disease using ctDNA fraction after completion of NAT in subgroups.
  • Table S1. Mutations targeted in reference samples.
  • Table S2. Expected mutation fractions in reference samples analyzed.
  • Table S3. Tumor and germline sequencing statistics.
  • Table S4. Oligonucleotide sequences used for sequencing library preparation.
  • Legends for data files S1 to S4

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Mutations detected in reference samples in Fig. 2.
  • Data file S2 (Microsoft Excel format). Mutations detected in reference samples in Fig. 3.
  • Data file S3 (Microsoft Excel format). Details of patient plasma samples and ctDNA tumor fraction.
  • Data file S4 (Microsoft Excel format). Mutations detected in patient plasma samples.